COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,609 Articles (22,913 medRxiv, 8,696 bioRxiv)

Most recent first Previous |  Page 2117: Articles 21161-21170  | Next

A lateral flow test detecting SARS-CoV-2 neutralizing antibodies
Wang, J. J., Zhang, N., Chen, S., Wu, J. V., Yang, X.
10.1101/2020.11.05.20222596 — Posted: 2020-11-10
Temporal Variations in the Intensity of Care Provided to Community and Nursing Home Residents Who Died of COVID-19 in Ontario, Canada
Brown, K. A., Daneman, N., Buchan, S. A., Chan, A. K., Stall, N. M.
10.1101/2020.11.06.20227140 — Posted: 2020-11-10
Performance of qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva
Yokota, I., Sakurazawa, T., Sugita, J., Iwasaki, S., Yasuda, K., Yamashita, N., Fujisawa, S., Nishida, M., Konno, S., Teshima, T.
10.1101/2020.11.06.20227363 — Posted: 2020-11-10
Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review
Senefeld, J., Klassen, S. A., Ford, S. K., Wiggins, C. C., Bostrom, B. C., Thompson, M. A., Baker, S. E., Nicholson, W. T., Johnson, P. W., Carter, R. E., Henderson, J. P., Hartman, W. R., Pirofski, L.-a., Wright, R. S., Fairweather, D., Bruno, K. A., Paneth, N. S., Casadevall, A., Joyner, M. J.
10.1101/2020.11.08.20224790 — Posted: 2020-11-10
A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
Mehta, R. M., Bansal, S., Bysani, S., Kalpakam, H.
10.1101/2020.11.05.20226373 — Posted: 2020-11-10 Discussion: Onsite
Risk factors for mortality of residents in nursing homes with Covid-19: a retrospective cohort study
Suner, C., Ouchi, D., Mas, M. A., Lopez Alarcon, R., Massot Mesquida, M., Negredo, E., Prat, N., Bonet Simo, J. M., Miralles, R., Teixido Colet, M., Verdaguer Puigvendrello, J., Henriquez, N., Marks, M., Ara, J., Mitja, O.
10.1101/2020.11.09.20228171 — Posted: 2020-11-10
A saliva-based RNA extraction-free workflow integrated with Cas13a for SARS-CoV-2 detection
Azmi, I., Faizan, M. I., Kumar, R., Yadav, S. R., Chaudhary, N., Singh, D. K., Butola, R., Ganotra, A., Joshi, G. D., Iqbal, J., Joshi, M. C., Ahmad, T.
10.1101/2020.11.07.20227082 — Posted: 2020-11-10 Discussion: Onsite
Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study
Madan, S., Rana, M., Gajjar, R., Shah, N., Thakkar, V., Shah, B., Dabhi, P., Patel, M., Shah, H., Chovatiya, R., Soni, M., Bapat, N., Patel, A.
10.1101/2020.11.07.20226837 — Posted: 2020-11-10 Discussion: Onsite
COVID-19 case management: The policy model in Morocco context
Bennis, I.
10.1101/2020.11.07.20227603 — Posted: 2020-11-10
Spatial dynamics of SARS-Cov-2 and reduced risk of contagion: evidence from the second Italian epidemic wave
Buonanno, P., Galletta, S., Puca, M.
10.1101/2020.11.08.20227934 — Posted: 2020-11-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).